Klaria Interim Report Q2 2021
Klaria Interim Report Q2 2021Summary of the interim report Positive results for the bioequivalence registration study with Sumatriptan Alginate Film SECOND QUARTER OF 2021 · Net sales amounted to 0.0 MSEK (0.0 MSEK · Other income amounted to 0.0 MSEK (1.1 MSEK) · R&D costs for the period amounted to 11.5 MSEK (9.2 MSEK) · Profit after tax amounted to -15.9 MSEK (-10.1 MSEK) · Earnings per share for the quarter amounted to -0.31 SEK (-0.24 SEK) · Cash flow from operating activities amounted to -13.5 MSEK (-13.4 MSEK) · Cash and cash equivalents on the balance